ELUTIA INC.

ELUT
About the company

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery.

Country: United StatesPrice: $0.82Market Cap: $36.4M

Investment snapshot

29%positive consensus
Scored 1d ago

Positive

5

BUY / PASS

Neutral / negative

2 / 9

NEUTRAL / FAIL

Median fair value

$6.67

+713.4% vs price

Models with upside

3 / 17

Positive margin of safety

Strongest signal

ELUT undervalued: all 3 models price fair value above $0.82 (median $6.67)

Key risk

No clean pass — all 8 investors flag at least one growth criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedPASSPASSFAILNEUTRALFAILFAILPASSPASSFAILBUYFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety+76.1%+94.1%N/AN/AN/AN/AN/A+87.7%N/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-13

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-13

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Where It Passes

  • Valuation models100% pass✓ 3▾

    ELUT undervalued: all 3 models price fair value above $0.82 (median $6.67)

    Graham fair value$3.43
    ✓Graham+76.1% margin vs $0.82
    Buffett fair value$13.96
    ✓Buffett+94.1% margin vs $0.82
    Pabrai fair value$6.67
    ✓Pabrai+87.7% margin vs $0.82

Where It Falls Short

  • Growth0% pass✓ 3✗ 10▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)P/E 0.9x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: -86.5% vs Rev: -52.8%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$-18.48 (2019) -> $0.87 (2025)
    ✓DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency1/7 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-15.0%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency4/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 44.7% -> 53.7%, operating margin -123.4% -> -218.9%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR-22.0%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Profitability13% pass✓ 11✗ 24▾

    14 of 16 flag ELUT's profitability — Graham, Buffett, Lynch +11 more

    Positive EPS (10 years)1/8 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)1/8 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-31.8%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-218.9% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$54.3M
    ✓BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)P/E 0.9x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE354.9%
    ✓Lynch> 15%
    EBIT / Enterprise Value-180.1%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-180.1%, ROC=N/A (invested capital <= 0)
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets85.61%
    ✓PiotroskiROA > 0
    ROA Change YoY-149.33% -> 85.61% (delta: +234.94%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-71.87%, ROA=85.61%
    ✗PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY46.4% -> 53.7%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue-286.2%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity354.9%
    ✓Dreman> 12%
    Margin of SafetyP/E=0.9x, P/B=1.4x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-31.8% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency1/7 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-279.0%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity354.9%
    ✓Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-123.4% (2023) -> -218.9% (2025)
    ✗TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 44.7% -> 53.7%, operating margin -123.4% -> -218.9%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+149.40%; #79/6340 (top 1.2%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+12.17%; #2636/3702 (top 71.2%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity+354.92%; #22/5226 (top 0.4%)
    ✓AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.7712; #5167/5884 (top 87.8%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years1/7 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Valuation15% pass✓ 10✗ 18▾

    11 of 13 flag ELUT's valuation — Graham, Lynch, Greenblatt +8 more

    Price / Book Value per Share1.4x
    ✗Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio1.4x
    ✓Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)P/E 0.9x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-180.1%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-180.1%, ROC=N/A (invested capital <= 0)
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS0.9x
    ✓Dreman< 12x✓Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Valuation ReasonablenessP/E=0.9x, OE Yield=144.1%
    ✓MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=0.9x, FCF Yield=-128.2%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=0.9x, P/B=1.4x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low134% of trailing low ($0.61)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+149.40%; #79/6340 (top 1.2%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.4209; #3184/6449 (top 49.4%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS0.9x
    ✓NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share1.44x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-91.8%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.2733; #3451/5247 (top 65.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-139.21%; #4132/4519 (top 91.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-27.43%; #4301/6202 (top 69.3%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Cash Flow20% pass✓ 2✗ 10▾

    8 of 10 flag ELUT's cash flow — Lynch, Piotroski, Dreman +5 more

    Free Cash Flow Proxy$54.3M
    ✓BuffettPositive and growing
    FCF Positive and Growing$-50.7M
    ✗LynchPositive and growing
    Operating Cash Flow$-44.8M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-71.87%, ROA=85.61%
    ✗PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldP/E=0.9x, FCF Yield=-128.2%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/7 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-134.5%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency0/7 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-50.7M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-139.21%; #4132/4519 (top 91.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Efficiency25% pass✓ 3✗ 8▾

    6 of 8 flag ELUT's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio2.63
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-855.6%
    ✗Buffett> 10%
    ROIC - WACC-865.6%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
    ✗Greenblatt> 25%
    Current Ratio Change YoY0.69 -> 2.22
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.40x -> 0.20x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities2.63
    ✓Dreman> 1.5
    Return on Invested Capital-93.6%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/2 years above 12% (latest -144.6%)
    ✗SleepROIC > 12% in a majority of years
  • Verdicts36% pass✓ 5✗ 9▾

    Split decision: 9 FAIL · 4 PASS · 2 NEUTRAL · 1 BUY

    Overall verdict
    ✗GrahamFAIL (3/9)✗BuffettFAIL (1/9)✗LynchFAIL (3/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 5)✓DremanPASS (5/11)✗MungerFAIL (1/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (0/6)✗MarksFAIL (1/5)✓AckmanPASS (4/9)✓TempletonPASS (4/8)✗SleepFAIL (1/6)✓AsnessBUY (Rank #593/2370 (Top 25.0%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Debt & Leverage50% pass✓ 9✗ 6▾

    6 of 12 pass — Buffett, Lynch, Munger +3 more object

    LT Debt vs Net Current AssetsLT Debt $8.1M vs NCA $26.1M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest Coverage
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.53
    ✗Lynch< 0.33
    Cash - Long-term Debt$21.0M
    ✓LynchPositive preferred
    LT Debt / Total Assets Change62.57% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities2.63
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.53
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.53
    ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-3.6x, D/EBITDA=N/A
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.53
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.5284; #2524/4210 (top 60.0%)
    ✗AsnessTop 30% of eligible cross-section

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Micro Cap($36.4M)
Revenue: $12.3M-15.0% YoY
Net Income: $53.4M+198.9% YoY

Financial Snapshot

Operating Margin-218.9%
Return on Equity192.9%
Debt / Equity--
Current Ratio2.22
EPS (Diluted)$0.87
Shares Retired−58.0% / −153.0% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2025

Issued 58.0% of shares last year, 153.0% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, depreciation amortization, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-03-13
FY 2024
Sources
  • 10-K · 2025-03-11
FY 2023
Sources
  • 10-K · 2024-03-11
FY 2022
Sources
  • 10-K · 2023-03-23
FY 2021
Sources
  • 10-K · 2022-03-08
Market Cap$36.4Mcurrent------$48.2Mest.$93.6Mest.$65.6Mest.$62.0Mest.$65.8Mest.
Revenue$9.9M↓53%$1.1M↓66%$2.4M↓61%$3.1M↓48%$12.3M↓15%$14.5M↓42%$24.7M↑4%$23.8M↓50%$47.4M
Operating Income-$27.8M↑12%-$6.9M↓32%-$8.0M↑19%-$6.3M↑20%-$26.9M↑12%-$30.7M↓1%-$30.5M↑13%-$35.2M↓53%-$23.0M
Net Income$54.4M↑305%-$1.3M↑67%-$7.6M↑20%-$7.5M↓90%$53.4M↑199%-$53.9M↓43%-$37.7M↓14%-$32.9M↓32%-$24.8M
EPS (Diluted)--$-0.04↑79%$-0.17↑35%$-0.17↑19%$0.87↑147%$-1.86↑10%$-2.07↑13%$-2.38$-2.38
Gross Margin59.0%↑28%61.7%↑11%59.6%↑22%57.9%↑42%53.7%↑16%46.4%↑4%44.7%↓8%48.8%↑22%40.1%
Operating Margin-279.0%↓87%-606.5%↓287%-327.9%↓108%-203.9%↓55%-218.9%↓3%-212.3%↓72%-123.4%↑16%-147.5%↓204%-48.6%
ROE354.9%↑489%———192.9%↑65%116.6%↑20%97.6%↓85%653.6%↑456%-183.7%
Total Debt$8.1M↓69%$8.1M↓69%------$23.9M↑1%$23.7M↓2%$24.3M↑31%$18.5M
Shareholders' Equity$15.3M↑135%$15.3M↑135%$15.7M↑138%$22.5M↑162%$27.7M↑160%-$46.3M↓20%-$38.6M↓667%-$5.0M↓137%$13.5M
Current Ratio2.63↑492%2.63↑492%1.77↑201%2.05↑151%2.22↑221%0.69↓5%0.73↓39%1.19↓35%1.82
Debt / Equity0.53↑189%0.53↑189%———-0.52↑16%-0.61↑87%-4.82↓453%1.37
Operating Cash Flow-$49.2M↓53%-$8.1M↓182%-$8.5M↓3%-$7.8M↑12%-$44.8M↓98%-$22.7M↓4%-$21.8M↓2%-$21.4M↓39%-$15.4M
Free Cash Flow-$50.7M↓52%-$8.2M↓132%-$8.6M↓3%-$8.3M↑9%-$46.7M↓100%-$23.3M↓5%-$22.1M↓1%-$22.0M↓39%-$15.8M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

ELUT vs Peers — Financial Grading

Revenue$12.3MBottom 25%
Net Income$53.4MMedian
ROE192.9%Top 25%
D/E—
Op. Margin-218.9%Bottom 25%
Curr. Ratio2.22Median
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11